Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BPTH
Previous Symbol
CUSIPN/A
Phone832-742-1357
Debt
Debt-to-Equity RatioN/A
Current Ratio4.51
Quick Ratio4.51
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$40,000.00
Price / Sales142.80
Cash FlowN/A
Price / CashN/A
Book Value$0.71 per share
Price / Book0.59
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-7,020,000.00
Net MarginsN/A
Return on Equity-128.86%
Return on Assets-113.36%
Miscellaneous
Employees9
Outstanding Shares13,600,000
Market Cap$5.85 million
OptionableNot Optionable
Bio-Path (NASDAQ:BPTH) Frequently Asked Questions
What is Bio-Path's stock symbol?
Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."
When did Bio-Path's stock split? How did Bio-Path's stock split work?
Shares of Bio-Path reverse split on the morning of Thursday, February 8th 2018. The 1-10 reverse split was announced on Friday, February 9th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 9th 2018. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 10 shares after the split.
How were Bio-Path's earnings last quarter?
Bio-Path Holdings Inc (NASDAQ:BPTH) announced its quarterly earnings data on Thursday, November, 15th. The company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.07. View Bio-Path's Earnings History.
When is Bio-Path's next earnings date?
Has Bio-Path been receiving favorable news coverage?
News coverage about BPTH stock has trended somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bio-Path earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the near term.
Who are some of Bio-Path's key competitors?
Some companies that are related to Bio-Path include Xenetic Biosciences (XBIO), Citius Pharmaceuticals (CTXR), Amarillo Biosciences (AMAR), Novelion Therapeutics (NVLN), Innovus Pharmaceuticals (INNV), Akari Therapeutics (AKTX), KITOV PHARMA LT/S (KTOV), Genprex (GNPX), NeuroVive Pharmaceutical (NEVPF), Edge Therapeutics (EDGE), ESSA Pharma (EPIX), Pulmatrix (PULM), Pain Therapeutics (PTIE), SUMMIT THERAPEU/S (SMMT) and RegeneRx Biopharmaceuticals (RGRX).
Who are Bio-Path's key executives?
Bio-Path's management team includes the folowing people:
- Mr. Peter H. Nielsen, Co-Founder, Chairman, CEO, Pres, CFO & Treasurer (Age 69)
- Mr. Douglas P. Morris, Co-Founder, Director of Investor Relations, Sec. & Director (Age 62)
- Mr. Anthony Price MBA, Director of Fin. and Accounting
- Dr. Ana Tari Ashizawa, Director of Research
- Mr. Michael Roberts, Assistant Director of Manufacturing & Supply
How do I buy shares of Bio-Path?
Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Bio-Path's stock price today?
One share of BPTH stock can currently be purchased for approximately $0.40.
How big of a company is Bio-Path?
Bio-Path has a market capitalization of $5.85 million and generates $40,000.00 in revenue each year. Bio-Path employs 9 workers across the globe.
What is Bio-Path's official website?
How can I contact Bio-Path?
Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected]
MarketBeat Community Rating for Bio-Path (NASDAQ BPTH)
MarketBeat's community ratings are surveys of what our community members think about Bio-Path and other stocks. Vote "Outperform" if you believe BPTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
